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Reverse geneticsBluetongue virus core protein VP6 is an ATP hydrolysis dependent RNA helicase. However, despite much
study, the precise role of VP6 within the viral capsid and its structure remain unclear. To investigate the
requirement of VP6 in BTV replication, we initiated a structural and biological study. Multinuclear
nuclear magnetic resonance spectra were assigned on his-tagged full-length VP6 (329 amino acid
residues) as well as several truncated VP6 variants. The analysis revealed a large structured domain with
two large loop regions that exhibit signiﬁcant conformational exchange. One of the loops (amino acid
position 34–130) could be removed without affecting the overall fold of the protein. Moreover, using a
BTV reverse genetics system, it was possible to demonstrate that the VP6-truncated BTV was viable in
BHK cells in the absence of any helper VP6 protein, suggesting that a large portion of this loop region
is not absolutely required for BTV replication.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Bluetongue virus (BTV), the etiological agent of Bluetongue
disease of livestock, is a member of the Orbivirus genus of the
Reoviridae family. BTV particles have three consecutive proteins
layers that are organized into two capsids; an outer capsid
comprising VP2 and VP5 and an inner icosahedral capsid (core)
composed of two major proteins, VP7 and VP3, which encloses
the three minor proteins, VP1, VP4 and VP6, in addition to the viral
genome. The viral genome consists of 10 linear dsRNA molecules,
segment 1 to segment 10 (S1-S10). In addition to 7 structural
proteins, BTV genome also encodes 3 or 4 nonstructural proteins
(NS1, NS2, NS3 and NS4) in infected host cells [1–3].
The catalytic activities of both VP1 and VP4 have been con-
ﬁrmed by a range of in vitro studies [4–8]. Furthermore, structural
studies have revealed their close association in a complex located
at the 5-fold vertices of the VP3 subcore [9,10]. In contrast, despite
considerable information regarding its enzymatic function of VP6
in vitro [11,12], little is known regarding its structure or location
in the BTV core. While VP6, like VP1 and VP4, is co-puriﬁed with
core from virus-infected cells, VP6 is not readily taken up intocore-like particles (CLPs) when co-expressed with major core
structural proteins VP3 and VP7 [10,13]. Furthermore, although
VP6 is likely to unwind dsRNA either ahead or behind the tran-
scribing polymerase [11,12], it is also possible that the helicase
activity could play an entirely different role in virus assembly.
Recently, we constructed VP6-deﬁcient BTV strains using a
reverse genetics (RG) system and a complementary BSR-VP6 cell
line, demonstrating that VP6-deﬁcient mutant viruses were repli-
cation-deﬁcient in non-complementary cells (normal BSR cells)
[14,15]. Moreover, we demonstrated that the BTV core particle,
puriﬁed from normal BSR cells infected with VP6-deﬁcient mutant
virus, contained neither the genomic dsRNA nor the two proteins
of polymerase complex, VP1 and VP4 [16]. Thus, it is reasonable
to hypothesize that VP6 plays a role in RNA packaging in addition
to its role as a helicase in BTV mRNA transcription [16].
In this study, to further understand the importance of VP6, we
assigned Multinuclear nuclear magnetic resonance (NMR) spectra
of VP6 to provide insight into the VP6 structure. Based on NMR-
derived secondary structure, it was possible to design a series of
truncated proteins removing dynamic loop regions. Most
importantly, in spite of the essential role of VP6 in the primary
replication cycle of BTV, we show that the region between aa 34
and aa 92 of this large loop is not required for viral replication.
However the second half of this loop (aa 93–130) plays an essential
role in virus replication.
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2.1. Cell lines
BSR cells (BHK-21 subclone) were maintained in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) (Sigma) supplemented with
4% (vol/vol) fetal bovine serum (FBS) (Life Technologies). The stable
cell line, BSR-VP6 [15], were grown in DMEM-4% FBS supple-
mented with 7.5 lg/ml of puromycin (Sigma).
Preparation of dsRNA was as described previously [17–20].2.2. Plasmids and BTV T7 transcripts
A bacterial expression plasmid for the fusion of BTV-10 VP6
protein incorporating N-terminal hexahistidine tag (his-tag) was
produced by inserting the coding region of S9 into the modiﬁed
bacteria expression vector, pRSETA-imperial. A region, which
includes transcript stabilizing sequence from gene 10 of phage
T7, the Xpress™ epitope, and the enterokinase cleavage recogni-
tion sequence, was replaced with the thrombin cleavage recogni-
tion sequence.
Mammalian expression plasmids for the RG system, pCAG-
PBTV1VP1, pCAG-PBTV1VP3, pCAG-PBTV1VP4, pCAG-PBTV10VP6,
pCAG-PBTV1VP7 and pCAG-PBTV1NS2, were as described previ-
ously [15,16]. T7 plasmids for BTV transcripts used in the RG sys-
tem were as described previously [15,18].
Modiﬁcation of VP6 and S9 was generated by site-directed
mutagenesis, using the method as described previously [21]. The
sequence of each modiﬁed VP6 and S9 plasmid was conﬁrmed.
Synthesis of uncapped BTV transcripts was performed as
described previously [15]. For synthesis of uncapped T7
transcripts, RiboMAX Large Scale RNA Production System-T7
(Promega) was used according to the manufacturer’s protocols.2.3. Expression and puriﬁcation of a series of BTV VP6 proteins in an
Escherichia coli strain
An E. coli strain, BL21, was transformed with each VP6 expres-
sion plasmid. The transformed cells were incubated in 10 ml of
LB broth containing 100 lg/ml of ampicillin (ABPC) at 37 C for
16 h. After incubation, 1 ml of culture was inoculated to 10 ml of
the fresh LB broth containing 100 lg/ml of ABPC and was incu-
bated at 37 C for 1 h. The expression of his-tagged VP6 was then
induced for 5 h with the presence of 0.5 mM of IPTG.
For the production of labelled NMR, sample BL21 (DE3) was
used. After the transformation, a clone for each protein was
selected and ampliﬁed in 1 L of LB broth upon reaching
OD600  0.3–0.5. The cell pellets were transferred from the culture
to 1 L of minimal media containing 15NH4Cl and 13C6-glucose in
D2O for efﬁcient 15N-13C-labelling and deuteration of VP6. Expres-
sion of the his-tagged protein was induced after 5 h by adding
0.5 mM IPTG, and then harvested after an overnight induction per-
iod at 28 C. Note that for the expression of mutated VP6 proteins,
an optimized expression protocol based on the double-colony
selection method described previously was used [22].
The cells were collected by centrifugation and lysed by
sonication. The his-tagged protein was puriﬁed by bench top chro-
matography using a nickel–nitrilotriacetic acid (Ni–NTA) resin. A
second step of size exclusion chromatography was carried out on
the previous protein enriched fractions. Protein samples were con-
centrated to 0.75 mM in 50 mM sodium phosphate pH7.5, 50 mM
NaCl, 50 mM L-arginine, 50 mM L-glutamic acid, 10 mM DTT and
10% D2O.2.4. Acquisition of NMR spectra
NMR spectra were collected at 298 K on Bruker DRX600 and
DRX800 spectrometers equipped with Z-shielded gradient triple
resonance cryoprobes. The chemical shifts of 1HN, 15N, 13Ca, 13Cb
and 13CO cross peaks were assigned using the double- and triple-
resonance heteronuclear three-dimensional NMR spectra and
in-house assignment algorithms [23].
2.5. Transfection of cells
Conﬂuent monolayers of BSR-VP6 cells were transfected, ﬁrst
with six mammalian expression plasmids (100 ng each), coding
VP1, VP3, VP4, VP6, VP7 and NS2, followed by the second transfec-
tion with ten BTV T7 transcripts (50 ng each) using Lipofectamine
2000 Reagent (Life technologies) as described previously [16]. At
6 h post second transfection, the culture medium was replaced
with fresh DMEM containing 5% FBS and the plates were incubated
at 35 C in 5% CO2 for 3 days to allow cytopathic effects (CPE) to
appear. Note that as the recovery efﬁciency should be low due to
uncapped transcription in the second transfection, the plaque-
puriﬁcation procedure was not performed after transfection in this
study.
2.6. BTV replication assay
To observe CPE, 10 ll of VP6-truncated BTV recovered from
transfected BSR-VP6 cells was inoculated to normal BSR cells and
the supernatant, containing viruses, was replaced with 1.5% low-
melting agar in D-MEM supplemented with 5% FBS. At 2 days
post-inoculation, cells were stained with 0.5% of crystal violet.
To determine the virus replications, each 100 ll of VP6-trun-
cated BTV recovered from transfected BSR-VP6 cells were once
ampliﬁed in BSR-VP6 cells (P0), followed by the second (P1) and
the third (P2) ampliﬁcation in normal BSR cells. The virus titer of
each collected supernatant (P0  P2) was determined by plaque
assay using BSR-VP6 cells.3. Results
3.1. Expression of VP6 in E. coli and structural characterization by
NMR
To facilitate the NMR study, BTV-10 VP6 was overexpressed
with an N-terminal his-tag in E. coli. The proteins were expressed
well in soluble form (data not shown). The NMR analysis was ﬁrst
performed on the full-length VP6 (329 residues). Sequence speciﬁc
assignment of NMR spectra of 15N, 13C-labelled VP6 could be com-
pleted for over half the protein sequence (Fig. 1A), whilst the
remaining sequence formed two large dynamic loops. Conforma-
tional exchange on intermediate timescale within these regions
broadened the majority of the NMR signals beyond detection. As
shown in Fig. 1B, the chemical shift index (CSI) plot for backbone
atoms of the full-length VP6 was obtained based on the sequential
resonance assignment of the triple-labeled protein. There were two
gaps in the assigned sequence (from aa 33 to aa 130 and aa 184 to
aa 231), which likely indicate the presence of dynamic loops that
exhibit conformation exchange, as the corresponding cross-peaks
did not appear in the spectra.
3.2. Design of the truncated BTV VP6 variants
The presence of the two dynamic loops poses a signiﬁcant
challenge for the high-resolution structural study of VP6, especially
as their signals are undetectable in NMR spectra and the
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Fig. 1. The sequence speciﬁc assignment of the 1H-15N-HSQC NMR spectrum of the 15N, 13C-labelled VP6. (A) Assignment on 15N-HSQC spectrum of 0.75 mM VP6 full-length.
(B) The CSI plot for the Ca, and CO atoms. The CSI plot of native VP6 carbon atoms is based on the sequential resonance assignment of the triply labeled protein mentioned
above. The CSI plot was generated using NMRview [26] and is shown below the amino acid sequences of the his-tagged VP6. The predicted secondary structure was shown
under the plot. The positions of ß-strands and a-helix, which were calculated from the atomic coordinates, were indicated as gray arrows and looped lines, respectively.
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fore designed several shorter constructs of the protein VP6 based
on our NMR assignment that either removed one or both loops
(Fig. 2A).
The four deletions were created in his-tagged VP6 protein. The
mutants of VP6, d1 and d2, lacked the ﬁrst loop, either a portion (aa
34–aa 92; d1) only or the complete loop region (aa 34–aa 130, d2)
of VP6. The third truncated VP6, d3, had a deletion of the second
loop region (aa 183–aa 220) and the last mutant VP6, d2.3, lacked
both loop regions (aa 34–aa 130 and aa 183–aa 220). To reduce any
detrimental effects on the stability of the core VP6 domain, we
substituted the ﬁrst loop in variants d1, d2 and d2.3 with 5 amino
acid residues, Gly-Ala-Gly-Ala-Gly (GAGAG). All truncated VP6
proteins were expressed in E. coli strain, BL21 (Fig. 2B). Truncations
of the loop between residues 183 and 220 rendered constructs
unstable, and the expressed protein were either insoluble, as for
d2.3VP6 construct, or not expressed at a detectable level, as for
d3VP6. However, deletion of the ﬁrst loop (residues 34–130) did
not affect expression yields or the protein structure as tested by
preliminary NMR spectra (data not shown). Therefore, labeledsamples were produced for construct d1VP6 and d2VP6, following
the protocol described previously for full-length VP6 (WTVP6).
Protein samples were concentrated to 0.75 mM in 50 mM
sodium phosphate pH7.5, 50 mM NaCl, 50 mM L-arginine, 50 mM
L-glutamic acid, 10 mM DTT and 10% D2O. By simple comparison
of the sequence speciﬁc assignment of WTVP6 on the 1H-15N-HSQC
spectrum shown in Fig. 1A, many of the signals could be assigned
unambiguously for the short deletion construct (d1VP6, data not
shown), demonstrating that the lack of this major loop did not
affect the structure of core domain, even when the entire loop
was removed (d2VP6, data not shown). NMR studies were contin-
ued using the construct d2VP6 since it is shorter than d1VP6, and
the expressed protein product was at a much higher level than that
of d1VP6 after puriﬁcation.
A 15N, 13C-double labeled sample of d2VP6 was expressed and
puriﬁed as described above. The sequence assignment of 15N-13C-
d2VP6 on the 1H-15N-HSQC spectrum was very similar to that of
WTVP6, suggesting that loss of the loop did not affect the overall
folding of the protein (Fig. 2C). The assignment of the sequence
was almost complete, with the exception of the residues from
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Fig. 2. Construction of the truncated VP6 variants. (A) Schematic representation of the changes introduced in the his-tagged VP6 of BTV. Either or both of two ‘‘invisible’’
regions were truncated. On the left, the name of mutation is indicated. Numbers indicate amino acid positions in VP6 where deletions were introduced. To keep ﬂexibility, the
amino acid sequence, GAGAG, was inserted into a truncated region of the ﬁrst loop. Total length of each protein is indicated. (B) Each VP6 variant was expressed in E. coli
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visible in the spectra. Although it was not possible to perform
three-dimensional structural calculations with this limited data,
it is clear that signiﬁcant portions of VP6 are not necessary for
keeping the structure in stable form.
3.3. VP6-truncated virus d1BTV replicates in normal cells but d2BTV
does not
NMR study revealed that two truncated VP6 mutants, d1 and
d2, possessed similar structures to full-length VP6 (WTVP6). To
determine whether these truncated VP6 proteins were still func-tional in BTV replication, the two VP6-truncated viruses, which
contained the same deletions in S9 RNA segment as those in his-
tagged VP6, were generated (Fig. 3). The two mutations designed
in S9 included either a half-deletion of the ﬁrst ﬂexible loop of
VP6 (nt 115–nt 291) (d1), or a whole deletion (nt 115–nt 405)
(d2) (Fig. 3A). The deleted regions in both d1 and d2 were substi-
tuted with the 15 mer-sequence coding 5 residues, GAGAG, in
frame.
Each virus was recovered in the BSR-VP6 complementing cell
line and the proﬁle of the genomic dsRNAs of each mutant virus
was analyzed by native-PAGE (Fig. 3B). The presence of the
designed truncation/substitution in each mutated virus was
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Fig. 3. Recovery of VP6-truncated BTV from complementing cell line BSR-VP6. (A)
Schematic representation of the changes introduced in the segment S9 of BTV. On
the left, the name of mutation is indicated. Numbers indicate nucleotide positions
in the S9 where deletions were introduced. The nucleotide sequence coding 5
amino acid residues, GAGAG, was inserted as indicated. Total length of each
segment is indicated. (B) Genomic dsRNA was puriﬁed from infected cells and
analyzed by nondenaturing-PAGE. (C) cDNA copies of S9 were synthesized from
isolated viral dsRNA and ampliﬁed by PCR (lanes 2–4). As a control, PCR products
were ampliﬁed from T7 plasmids of S9 variants (lanes 5–7). Markers (lane 1) are
indicated. The numbers on the left indicate the markers nucleotides.
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Fig. 4. Characterization of VP6-truncated BTV in normal BSR cells. (A) Normal BSR
cells infected with 10 ll of VP6-truncated BTV were stained with 0.5% crystal violet
at 2 days post-infection. (B) Each 100 ll of VP6-truncated BTV recovered from
transfected BSR-VP6 cells were once ampliﬁed in BSR-VP6 cells (P0), followed by
the second (P1) and the third (P2) ampliﬁcation in normal BSR cells. The virus titer
of each collected supernatant (P0  P2) was determined by plaque assay using BSR-
VP6 cells and the infectivity was shown as a fold of P0 (Mean ± SD). (C) Pattern of
genomic dsRNA puriﬁed from cells infected with d1BTV and d2BTV (P0  P2) was
analyzed by nondenaturing-PAGE. Position of the corresponding S9 in each VP6-
truncated virus is indicated with white arrows.
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(Fig. 3C and not shown). No unexpected changes were detected,
indicating that all mutant segments were functional in genome
packaging and replication in complementary BSR-VP6 cells.
To assess the replication capability of the VP6 mutant viruses in
normal BSR cells, 10 ll of VP6-truncated BTV recovered from trans-
fected BSR-VP6 cells was inoculated into normal BSR cells. At
2 days post-inoculation, the presence of CPE was observed
(Fig. 4A). Surprisingly, the inoculation of d1BTV induced pro-
nounced CPE to the normal BSR cells whereas no CPE was observed
in d2BTV-infected BSR. Note that this is the ﬁrst report of a viable
VP6-truncated BTV in normal BSR without any helper VP6 protein.
To further conﬁrm viability of d1BTV in normal BSR, the infec-
tious virus titer (cell-free, supernatant virus) and the proﬁle of
genomic dsRNAs extracted from infected cells in each virus pas-
sage (P0  P2) were determined (Fig. 4B and C). The titer of
d1BTV dramatically increased during passage using normal BSR
(Fig. 4B, dark gray columns). Moreover, the dsRNA proﬁle of
d1BTV in each passage showed that the truncation was absolutely
retained (Fig. 4C). The presence of the mutation in each passage
was conﬁrmed by sequencing the corresponding RT-PCR product
(data not shown). In contrast, d2BTV could not replicate in normal
BSR at all (Fig. 4B, light gray columns). In addition, the genomic
dsRNAs of d2BTV were only detectable in BSR-VP6 cells (Fig. 4C,
P0). These results clearly suggested that a part of VP6 (nt 115–nt
291; aa 34–92) was not required for BTV replication in BSR cells,
whereas a latter half of the ﬁrst ﬂexible region may possess the
unknown but essential function in the virus replication.4. Discussion
BTV, a member of the Orbivirus genus, is unique among the Reo-
viridae family in encoding VP6, a protein with nucleoside triphos-
phatase, RNA binding, and helicase activity in vitro [11,12,24]. In
addition, we recently reported that VP6 plays an essential role in
primary replication and possibly in RNA packaging during core
assembly as well [14–16]. Although it is reasonable to hypothesize
that VP6 also plays a role in RNA packaging in addition to its role as
a RNA helicase, the exact function of BTV VP6 in BTV biology still
remains to be addressed, as to date it has not been possible to
determine its structure or its precise location within the core. In
this paper we have presented a preliminary NMR study on BTV
608 E. Matsuo et al. / Biochemical and Biophysical Research Communications 451 (2014) 603–608VP6 to understand further its function in BTV replication. Using a
combination of solution NMR spectroscopy, RG system and site-
speciﬁc mutagenesis, we have demonstrated that a signiﬁcant frag-
ment of VP6 is not absolutely necessary for BTV replication, at least
in cell culture.
Despite decades of attempts to generate an atomic structure of
VP6, it has not been possible to crystallize the protein. VP6 protein
is highly soluble and can only be precipitated in the presence of up
to 90% (wt/wt) of the ammonium sulfate [12]. We therefore used
NMR to understand the structural features of the protein in solu-
tions. This data showed that half of the protein forms two large
loop regions, whose conformational dynamics makes them unde-
tectable by NMR as the signals are broadened. These dynamic
regions in VP6 likely contribute to the high solubility of VP6,
resulting in difﬁculties for crystallization. Since the truncation of
the ﬁrst large loop of VP6 retains the same core structure to full-
length VP6, it is possible that this truncation may allow future
crystallization of VP6.
One of the truncations, the complete truncation of the ﬁrst loop
(d2), lost the function of VP6 in BTV replication whereas the half
truncation of that (d1) still retained the active function. The lack
of 38 residues between amino acid position 93 and 130 in VP6 is
likely to be critical in BTV replication. Previous in vitro studies
showed that this region of d2VP6 contains ATP-binding/ATPase
motif [11], suggesting that d2BTV could not replicate possibly due
to loss of ATPase activity. However, the program ATPint, which pre-
dicts ATP-interacting residues, (http://www.imtech.res.in/raghava/
atpint/), suggests that the 10 residues in d2VP6, which included the
5 linker residues inserted into the truncated loop, may interact with
ATP. Therefore, it is conceivable that the insertion of the linker may
have created an unexpected ATPase motif that allows d2VP6 to
complement for VP6’s ATPase function during BTV replication.
Recently, the fourth nonstructural protein of BTV, NS4, was
identiﬁed [1]. NS4 is encoded by an ORF (nt 182–415) in S9 over-
lapping the ORF encoding VP6. The deletion of NS4 by removing
the initiation codon (nt 182 in S9) and the induction of two stop
codons at amino acid position 24 and 67 of NS4 was dispensable
for BTV replication [1]. However, this mutated S9 could still
express a part of C-terminal region of NS4 translated from the ini-
tiation codon at position nt 323, originally coding methionine at
amino acid position 48 in NS4 and terminating at the inducing stop
codon. In our mutated S9, the deletion of a whole ﬁrst ﬂexible
region (d2S9) resulted in the complete deletion of the NS4 protein.
On the other hand, d1S9 still retained the ability to express 30
residues of C-terminal region of NS4 as ATG at position nt 161 in
d1S9, which is matched with nt 323 of WTS9, and could work as
initiation codon with medium Kozak context, gAgaATGc [25]. Thus,
although further studies are necessary, it is still possible that
C-terminal of NS4 may have an important role in BTV replication.
The deletion of VP6 was believed to be replication-defective as
VP6 protein is essential for the primary replication [14–16]. How-
ever, here we ﬁrst demonstrated that the truncation of 59 residues
in VP6 (177 nt of S9) did not affect BTV replication. Moreover, the
deletion was stable over passage of d1BTV in mammalian cells.
Further study is required to clarify whether the truncated region
is deﬁnitely unnecessary for BTV replication in both insect cells
and mammalian cells as well as in natural hosts.
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